NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
2.040
-0.010 (-0.49%)
At close: May 9, 2025, 4:00 PM
1.974
-0.066 (-3.22%)
After-hours: May 9, 2025, 4:07 PM EDT
NRx Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for NRx Pharmaceuticals stock have an average target of 28.5, with a low estimate of 18 and a high estimate of 46. The average target predicts an increase of 1,297.06% from the current stock price of 2.04.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for NRx Pharmaceuticals stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 3 | 3 | 4 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $31 | Strong Buy | Maintains | $31 | +1,419.61% | Apr 30, 2025 |
Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $45 → $46 | Strong Buy | Maintains | $45 → $46 | +2,154.90% | Apr 29, 2025 |
BTIG | BTIG | Strong Buy Initiates $18 | Strong Buy | Initiates | $18 | +782.35% | Apr 2, 2025 |
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $31 | Strong Buy | Maintains | $31 | +1,419.61% | Mar 31, 2025 |
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $31 | Strong Buy | Maintains | $31 | +1,419.61% | Mar 24, 2025 |
Financial Forecast
Revenue This Year
n/a
from 1.20B
Revenue Next Year
n/a
EPS This Year
n/a
from -2.36
EPS Next Year
0.78
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 40.1M | 189.3M | 544.6M | ||
Avg | 34.8M | 113.6M | 296.7M | ||
Low | 29.4M | 41.6M | 61.9M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -96.7% | 444.2% | 379.5% | ||
Avg | -97.1% | 226.5% | 161.3% | ||
Low | -97.6% | 19.5% | -45.5% |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | 0.06 | 1.62 | 5.18 |
Avg | - | 0.78 | 2.78 |
Low | -0.06 | -0.01 | 0.51 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | - | - | 563.4% |
Avg | - | - | 256.2% |
Low | - | - | -34.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.